Using machine learning to predict drug approvals
Published December 8, 2019
25 min
    Add to queue
    Copy URL
    Show notes
    One of the hottest areas in data science and machine learning right now is healthcare: the size of the healthcare industry, the amount of data it generates, and the myriad improvements possible in the healthcare system lay the groundwork for compelling, innovative new data initiatives. One spot that drives much of the cost of medicine is the riskiness of developing new drugs: drug trials can cost hundreds of millions of dollars to run and, especially given that numerous medicines end up failing to get approval from the FDA, pharmaceutical companies want to have as much insight as possible about whether a drug is more or less likely to make it through clinical trials and on to approval. Professor Andrew Lo and collaborators at MIT Sloan School of Management is taking a look at this prediction task using machine learning, and has an article in the Harvard Data Science Review showing what they were able to find. It’s a fascinating example of how data science can be used to address business needs in creative but very targeted and effective ways. Relevant links:
        0:00:00 / 0:00:00